OKUR Stock — OnKure Therapeutics Inc.: Cash, EV, Pipeline

What they do

OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies.

Source: 10-K FY2025 via SEC EDGAR

Share price

$2.87

Market cap

$116.0M

Cash

$163.3M

Enterprise value

-$47.3M

Balance sheet

Cash	$163.3M
Debt	$0.0M
Net cash	$163.3M
Enterprise value	-$47.3M
Basic shares	40.5M shares
Fully diluted shares	45.9M shares
Fully diluted market cap	$131.6M
Cash per share	$4.03
Quarterly burn	$10.4M
Cash runway	17.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

40.5M

Pre-funded warrants

0.0M

Options

5.3M

RSUs

0.0M

Warrants

—

Converts

—

Conv preferred

—

ESPP reserve

—

FDSO

45.9M

Cap table as of 2026-11-04.

Price history

Loading OKUR daily closes…

Loading price history…

Next catalyst

OKI-219 · Feb 11 - Mar 25 in 14 wks · Phase 1 · Advanced Cancer; Breast Cancer; Advanced Solid Tumors

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25 in 14 wks	OKI-219	Phase 1	Advanced Cancer; Breast Cancer; Advanced Solid Tumors	—
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	OKI-345 IND submission for breast cancer	Not disclosed	breast cancer	1H 2027
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	OKI-355 IND submission for vascular anomalies	Not disclosed	vascular anomalies	1H 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

OKI-345

Preclinical · Active Modality: small molecule (next-generation PI3Kα pan-mutant inhibitor)

Target PI3Kα (mutant)

Indications

Breast cancer (Preclinical)

Catalysts

— H1 2027

Status note Designed to selectively inhibit mutant PI3Kα across all hotspot mutations while sparing wild-type PI3Kα.

OKI-355

Preclinical · Active Modality: small molecule (next-generation PI3Kα pan-mutant inhibitor)

Target PI3Kα (mutant)

Indications

Vascular anomalies (Preclinical)

Catalysts

— H1 2027

Status note Designed to selectively inhibit mutant PI3Kα across all hotspot mutations while sparing wild-type PI3Kα.

OKI-219

Phase 1 · Active Modality: small molecule (mutant-selective PI3Kα inhibitor)

Target PI3Kα H1047R (mutant)

Indications

Solid tumors including PI3KαH1047R-mutant breast cancer (Phase 1)

Status note Former lead candidate; first-in-human Phase 1 PIKture-01 trial (monotherapy and combination arms). Excluded from the 2026 Private Placement R&D spend, which funds only the vascular anomalies and breast cancer (OKI-345/355) programs.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OKI-219
Lead indication	Advanced Cancer; Breast Cancer; Advanced Solid Tumors
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06239467	Phase 1	Active, not recruiting	Sponsor	OnKure, Inc.	—	Advanced Cancer; Breast Cancer; Advanced Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for OnKure, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	3,235,778	+1,256,806	0.38%	2026-08-14
ADAR1 Capital Management	2,238,684	-196,257	0.48%	2026-08-14
Vivo Capital	1,927,710	no change	0.80%	2026-08-14
Logos Global Management	963,855	+963,855	0.19%	2026-08-14
Stonepine Capital	130,684	-1,894	0.45%	2026-08-17
Aisling Capital	88,607	no change	0.09%	2026-08-13

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

OKUR — OnKure Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

OKUR — OnKure Therapeutics Inc.